Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The novel attachment inhibitor led to viral suppression in 60% of people with extensive prior treatment.
The agency has also lowered the weight threshold for film-coated tablets of the integrase inhibitor.
The immune modulator Pomalyst led to remission in two thirds of people with AIDS-related KS.
Whether given every four or eight weeks, long-acting injections of cabotegravir and rilpivirine suppressed HIV equally well.
Tests like the one approved this week can show who is likely to be immune, but it’s not yet clear how long such immunity lasts.
ViiV applies for FDA approval of HIV drug fostemsavir
The Food and Drug Administration declined approval of ViiV Healthcare’s injectable HIV regimen Cabenuva.
Read the digital edition!
The FDA recently held up the U.S. approval based on concerns over the monthly injectable regimen’s manufacturing.
The attachment inhibitor performed well as an adjunct to an optimized antiretroviral regimen among those with multidrug-resistant HIV.
The Food and Drug Administration approves once-daily Descovy for PrEP.
The authors of the largest study to date to analyze condoms’ failure rate are pushing the FDA to finally approve them for anal sex use.
Acting Commissioner Ned Sharpless will return to lead the National Cancer Institute.
The new indication is for prevention of sexually transmitted HIV, with the exception of transmission via receptive vaginal sex.
The indication for AbbVie’s regimen includes those with compensated cirrhosis.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.